Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuren Pharmaceuticals Ltd.

http://www.neurenpharma.com

Latest From Neuren Pharmaceuticals Ltd.

Acadia’s Daybue Gets First Approval In Rett Syndrome

Daybue is the first drug approved to treat the rare neurodevelopmental disorder Rett syndrome, despite high clinical trial incidence of diarrhea. Product labeling includes clinician guidance for the side effect.

Approvals Rare Diseases

With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate

Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.

Rare Diseases Business Strategies

Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky

Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.

Clinical Trials Rare Diseases
See All

Company Information

UsernamePublicRestriction

Register